Atea Pharmaceuticals Inc. (NASDAQ: AVIR) is -24.12% lower on its value in year-to-date trading and has touched a low of $3.15 and a high of $9.79 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AVIR stock was last observed hovering at around $3.63 in the last trading session, with the day’s gains setting it 0.02% off its average median price target of $4.00 for the next 12 months. It is also 54.37% off the consensus price target high of $8.00 offered by 4 analysts, but current levels are 8.75% higher than the price target low of $4.00 for the same period.
Currently trading at $3.65, the stock is -0.33% and -14.24% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.41 million and changing 0.55% at the moment leaves the stock -38.76% off its SMA200. AVIR registered -33.64% loss for a year compared to 6-month loss of -49.09%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The stock witnessed a -13.30% gain in the last 1 month and extending the period to 3 months gives it a -16.95%, and is 6.73% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.24% over the week and 5.54% over the month.
Distance from 52-week low is 15.87% and -62.72% from its 52-week high.
Atea Pharmaceuticals Inc. (AVIR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Atea Pharmaceuticals Inc. (AVIR) is a “Hold”. 4 analysts offering their recommendations for the stock have an average rating of 2.60, where 2 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Atea Pharmaceuticals Inc. is expected to release its quarterly report on 05/10/2023.The EPS is expected to shrink by -201.40% this year
Atea Pharmaceuticals Inc. (AVIR) Top Institutional Holders
The shares outstanding are 83.29M, and float is at 75.70M with Short Float at 2.38%.
Atea Pharmaceuticals Inc. (AVIR) Insider Activity
A total of 2 insider transactions have happened at Atea Pharmaceuticals Inc. (AVIR) in the last six months, with sales accounting for 2 and purchases happening 0 times. The most recent transaction is an insider sale by BERGER FRANKLIN M, the company’s Director. SEC filings show that BERGER FRANKLIN M sold 16,166 shares of the company’s common stock on Nov 14 at a price of $5.16 per share for a total of $83352.0. Following the sale, the insider now owns 0.78 million shares.
Atea Pharmaceuticals Inc. disclosed in a document filed with the SEC on Nov 11 that BERGER FRANKLIN M (Director) sold a total of 25,500 shares of the company’s common stock. The trade occurred on Nov 11 and was made at $5.15 per share for $0.13 million. Following the transaction, the insider now directly holds 0.79 million shares of the AVIR stock.
Atea Pharmaceuticals Inc. (AVIR): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 22.48% up over the past 12 months and Merck & Co. Inc. (MRK) that is 38.38% higher over the same period. Pfizer Inc. (PFE) is -22.91% down on the 1-year trading charts.